Found: 3
Select item for more details and to access through your institution.
Population Pharmacokinetics and Dosing Simulations for Aripiprazole 2‐Month Ready‐to‐Use Long‐Acting Injectable in Adult Patients With Schizophrenia or Bipolar I Disorder.
- Published in:
- Clinical Pharmacology in Drug Development, 2024, v. 13, n. 6, p. 631, doi. 10.1002/cpdd.1397
- By:
- Publication type:
- Article
Aripiprazole Plasma Concentrations Delivered from Two 2-Month Long-Acting Injectable Formulations: An Indirect Comparison.
- Published in:
- Neuropsychiatric Disease & Treatment, 2023, v. 19, p. 1409, doi. 10.2147/NDT.S412357
- By:
- Publication type:
- Article
A Randomized, Open-Label, Multiple-Dose, Parallel-Arm, Pivotal Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Aripiprazole 2-Month Long-Acting Injectable in Adults With Schizophrenia or Bipolar I Disorder.
- Published in:
- CNS Drugs, 2023, v. 37, n. 4, p. 337, doi. 10.1007/s40263-023-00996-8
- By:
- Publication type:
- Article